🟢 NanoViricides is trading 5.35% up in after-hours trading on optimism over upcoming oral Ebola trial

NanoViricides is trading 5.35% up at $1.28 after-hours on optimism following the September 15 announcement that its Phase II NV-387 oral-gummy Ebola trial in the Democratic Republic of Congo is expected to begin dosing the following week.

• Trial registered in the Pan African Clinical Trials Registry.
• Regular-session gains: 15.71% on September 16, 2026.
• No separate September 16 earnings release or late-breaking corporate announcement identified; market mixed after the Federal Reserve raised rates, making macro sentiment less likely the primary driver.